Acetylcysteine injection and preparation method thereof

By adding stabilizers and antioxidants in an oxygen-free nitrogen environment and using a macromolecular polysaccharide protective layer, the problem of easy degradation of acetylcysteine ​​injection is solved, improving its stability and storage time, and ensuring Safe for medication.

CN118948758AActive Publication Date: 2024-11-15峨眉山通惠制药有限公司
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411030790.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The existing acetylcysteine ​​injection is prone to degradation during the preparation process, resulting in high impurity content and poor storage stability, which affects the safety of medication.

Method used

Prepare acetylcysteine ​​injection in an oxygen-free nitrogen environment, add stabilizer zinc sulfate and antioxidant disodium edelic acid, and use macromolecular polysaccharides such as Poria cocos polysaccharide as protective layer, and treat it by autoclaving steam. Reduce oxidation risks and impurity generation.

Benefits of technology

It significantly improves the stability of acetylcysteine ​​injection, reduces the impurity content, extends the storage time of the drug, and enhances the safety of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004969871990000101
    Figure BDA0004969871990000101
  • Figure BDA0004969871990000111
    Figure BDA0004969871990000111
  • Figure BDA0004969871990000121
    Figure BDA0004969871990000121
Patent Text Reader

Abstract

The invention discloses an acetylcysteine injection and a preparation method thereof, and belongs to the technical field of medicine injection preparation, the injection comprises the following components by weight: 1%-4% of acetylcysteine, 2%-8% of a stabilizer, 0.01%-0.05% of an antioxidant, and the balance of water; wherein the stabilizer comprises zinc sulfate and polyporus polysaccharide. The acetylcysteine injection has the advantages of high stability, long preservation time, difficulty in decomposition and deterioration of effective components and low impurity content, and can effectively solve the problem that the acetylcysteine injection in the prior art is easy to degrade.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug injections, and particularly relates to an acetylcysteine ​​injection and a preparation method thereof. Background Art

[0002] Acetylcysteine ​​is a precursor of reduced glutathione, which can remove oxygen free radicals in the body and protect liver cells. Acetylcysteine ​​injection is a liver-protecting drug, mainly used for the early treatment of liver failure, which can reduce bilirubin and increase prothrombin activity.

[0003] The preparation process of existing acetylcysteine ​​injection includes preparing a certain concentration of NaOH solution for dissolving acetylcysteine ​​and disodium edetate, then constant volume, adjusting pH, filtering and sterilizing, and filling to obtain acetylcysteine ​​injection. The complicated preparation steps of existing acetylcysteine ​​injection can cause the acetylcysteine ​​raw material to degrade during the preparation process, so that the prepared acetylcysteine ​​injection has high impurity content and many types, and the impurity growth is obvious during storage. Therefore, developing a acetylcysteine ​​injection with low impurity content and high storage stability is of great significance to improving the drug safety of patients. Summary of the invention

[0004] In view of the above-mentioned deficiencies in the prior art, the present invention provides an acetylcysteine ​​injection and a preparation method thereof. The acetylcysteine ​​injection has the advantages of strong stability, long shelf life, effective ingredients that are not easy to decompose and deteriorate, and low impurity content, and can effectively solve the problem of easy degradation of the acetylcysteine ​​injection in the prior art.

[0005] To achieve the above purpose, the technical solution adopted by the present invention to solve the technical problem is:

[0006] An acetylcysteine ​​injection comprises the following components in weight percentage: 1%-4% acetylcysteine, 2%-8% stabilizer and 0.01-0.05% antioxidant, and the rest is water.

[0007] Furthermore, the invention comprises the following components in weight percentage: 3%-4% acetylcysteine, 5%-8% stabilizer, 0.02%-0.03% antioxidant, and the rest is water for injection.

[0008] Furthermore, the stabilizer includes zinc sulfate and polyporus polysaccharide.

[0009] Furthermore, the mass proportion of zinc sulfate is 3%-4%, and the mass proportion of Poria polysaccharide is 2%-4%.

[0010] Furthermore, the antioxidant is disodium edetate.

[0011] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0012] (1) Add zinc sulfate and acetylcysteine ​​to oxygen-free water for injection in sequence at 40-50° C. and nitrogen environment, stir until dissolved, and adjust the pH of the solution to 6-8 to prepare an acetylcysteine ​​solution;

[0013] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0014] (3) Adding Polyporus polysaccharide to anaerobic water for injection under nitrogen atmosphere and stirring until dissolved to prepare Polyporus polysaccharide solution;

[0015] (4) Under a nitrogen environment, the edetate disodium solution and the polyporus polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, stirred and mixed, fixed to volume, and then filtered, packaged, and sterilized by high-pressure steam to obtain the product.

[0016] Furthermore, in step (1), after the zinc sulfate is dissolved, acetylcysteine ​​is added thereto.

[0017] Furthermore, the pore size of the filtering device in step (4) is 0.22 microns.

[0018] Furthermore, in step (4), the high pressure steam sterilization temperature is 113-123° C., and the sterilization time is 10-15 min.

[0019] The beneficial effects produced by the present invention are:

[0020] In the present invention, oxygen-free water for injection is used as a solvent under a nitrogen environment, which can reduce the contact between acetylcysteine ​​and oxygen from the source, reduce the risk of oxidation during the preparation process, and improve the effectiveness of the drug.

[0021] In the present invention, a stabilizer is added to improve the stability of acetylcysteine ​​and prevent it from being oxidized and decomposed during storage. Specifically, zinc sulfate is first dissolved during the preparation process to prepare a zinc sulfate solution, and then acetylcysteine ​​is added thereto. During the dissolution process of acetylcysteine, the sulfhydryl groups inside the solution are complexed with zinc ions in the solution, thereby improving the stability of the sulfhydryl groups, thereby improving the stability of acetylcysteine ​​and reducing the risk of being oxidized. Then, a disodium edetate solution and a polyporus polysaccharide solution are prepared. Disodium edetate has strong antioxidant properties and can preferentially combine with metal ions and oxygen to assist in improving the stability of acetylcysteine. Polyporus polysaccharide is a macromolecular polysaccharide component. During the stirring process of the solution, the macromolecular polysaccharide can serve as a protective layer to wrap acetylcysteine ​​inside the macromolecular polysaccharide, thereby further improving the stability of acetylcysteine ​​and preventing it from being oxidized during storage, thereby improving the stability of acetylcysteine ​​and reducing the content of impurities in the injection.

[0022] The preparation method of the present invention is operated in a nitrogen environment throughout the process, which reduces the participation of oxygen from the source and improves the stability of the injection. The preparation method of the present application is simple, easy to operate, and can be applied in batches. DETAILED DESCRIPTION

[0023] In order to make the purpose, technical scheme and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention, that is, the embodiments described are only part of the embodiments of the present invention, rather than all of the embodiments.

[0024] Therefore, the following detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without making creative work are within the scope of protection of the present invention.

[0025] It should be noted that relational terms such as "first" and "second" are used only to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprises" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.

[0026] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0027] Example 1

[0028] An acetylcysteine ​​injection comprises the following components in percentage by weight: 3% acetylcysteine, 2% zinc sulfate, 2% polyporus polysaccharide and 0.01% edetate disodium, and the remainder is water.

[0029] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0030] (1) Add zinc sulfate to oxygen-free water for injection at 40° C. under nitrogen atmosphere, stir until dissolved, then add acetylcysteine ​​thereto, stir until dissolved, and adjust the pH of the solution to 7 with sodium hydroxide solution to prepare an acetylcysteine ​​solution;

[0031] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0032] (3) Adding Polyporus polysaccharide to anaerobic water for injection under nitrogen atmosphere and stirring until dissolved to prepare Polyporus polysaccharide solution;

[0033] (4) Under a nitrogen environment, the edetate disodium solution and the polyporus polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, and the mixture is stirred and mixed. The pH value of the solution is adjusted to 7 with hydrochloric acid or sodium hydroxide, and the volume is constant. The mixture is then filtered and packaged using an aluminum membrane with a pore size of 0.22 μm, and sterilized with high-pressure steam at 113° C. for 15 min to obtain the product.

[0034] Example 2

[0035] An acetylcysteine ​​injection comprises the following components in percentage by weight: 3% acetylcysteine, 4% zinc sulfate, 4% polyporus polysaccharide and 0.05% edetate disodium, and the remainder is water.

[0036] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0037] (1) adding zinc sulfate to oxygen-free water for injection at 50° C. under nitrogen atmosphere, stirring until dissolved, then adding acetylcysteine ​​thereto, stirring until dissolved, and adjusting the pH of the solution to 8 with sodium hydroxide solution to prepare an acetylcysteine ​​solution;

[0038] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0039] (3) Adding Polyporus polysaccharide to anaerobic water for injection under nitrogen atmosphere and stirring until dissolved to prepare Polyporus polysaccharide solution;

[0040] (4) Under a nitrogen environment, the edetate disodium solution and the polyporus polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, and the mixture is stirred and mixed. The pH value of the solution is adjusted to 7 with hydrochloric acid or sodium hydroxide, and the volume is constant. The mixture is then filtered and packaged using an aluminum membrane with a pore size of 0.22 μm, and sterilized with high-pressure steam at 123° C. for 10 min to obtain the product.

[0041] Example 3

[0042] An acetylcysteine ​​injection comprises the following components in percentage by weight: 4% acetylcysteine, 3% zinc sulfate, 2% polyporus polysaccharide and 0.02% edetate disodium, and the remainder is water.

[0043] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0044] (1) Add zinc sulfate to oxygen-free water for injection at 50° C. under nitrogen atmosphere, stir until dissolved, then add acetylcysteine ​​thereto, stir until dissolved, and adjust the pH of the solution to 6 with sodium hydroxide solution to prepare an acetylcysteine ​​solution;

[0045] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0046] (3) Adding Polyporus polysaccharide to anaerobic water for injection under nitrogen atmosphere and stirring until dissolved to prepare Polyporus polysaccharide solution;

[0047] (4) Under a nitrogen environment, the edetate disodium solution and the polyporus polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, and the mixture is stirred and mixed. The pH value of the solution is adjusted to 7 with hydrochloric acid or sodium hydroxide, and the volume is fixed. The mixture is then filtered and packaged using an aluminum membrane with a pore size of 0.22 μm, and sterilized with high-pressure steam at 117° C. for 15 min to obtain the product.

[0048] Example 4

[0049] An acetylcysteine ​​injection comprises the following components in percentage by weight: 4% acetylcysteine, 4% zinc sulfate, 3% polyporus polysaccharide and 0.03% edetate disodium, and the remainder is water.

[0050] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0051] (1) Add zinc sulfate to oxygen-free water for injection at 45° C. under nitrogen atmosphere, stir until dissolved, then add acetylcysteine ​​thereto, stir until dissolved, and adjust the pH of the solution to 7 with sodium hydroxide solution to prepare an acetylcysteine ​​solution;

[0052] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0053] (3) Adding Polyporus polysaccharide to anaerobic water for injection under nitrogen atmosphere and stirring until dissolved to prepare Polyporus polysaccharide solution;

[0054] (4) Under a nitrogen environment, the edetate disodium solution and the polyporus polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, and the mixture is stirred and mixed. The pH value of the solution is adjusted to 7 with hydrochloric acid or sodium hydroxide, and the volume is fixed. The mixture is then filtered and packaged using an aluminum membrane with a pore size of 0.22 μm, and sterilized with high-pressure steam at 120° C. for 15 min to obtain the product.

[0055] Comparative Example 1

[0056] An acetylcysteine ​​injection comprises the following components in percentage by weight: 4% acetylcysteine, 3% polyporus polysaccharide and 0.03% disodium edetate, and the remainder is water.

[0057] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0058] (1) Add acetylcysteine ​​to oxygen-free water for injection at 45° C. under nitrogen atmosphere, stir until dissolved, and adjust the pH of the solution to 7 with sodium hydroxide solution to prepare an acetylcysteine ​​solution;

[0059] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0060] (3) Adding Polyporus polysaccharide to anaerobic water for injection under nitrogen atmosphere and stirring until dissolved to prepare Polyporus polysaccharide solution;

[0061] (4) Under a nitrogen environment, the edetate disodium solution and the polyporus polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, and the mixture is stirred and mixed. The pH value of the solution is adjusted to 7 with hydrochloric acid or sodium hydroxide, and the volume is fixed. The mixture is then filtered and packaged using an aluminum membrane with a pore size of 0.22 μm, and sterilized with high-pressure steam at 120° C. for 15 min to obtain the product.

[0062] Comparative Example 2

[0063] An acetylcysteine ​​injection comprises the following components in percentage by weight: 4% acetylcysteine, 4% zinc sulfate and 0.03% disodium edetate, and the remainder is water.

[0064] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0065] (1) Add zinc sulfate to oxygen-free water for injection at 45° C. under nitrogen atmosphere, stir until dissolved, then add acetylcysteine ​​thereto, stir until dissolved, and adjust the pH of the solution to 7 with sodium hydroxide solution to prepare an acetylcysteine ​​solution;

[0066] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0067] (4) Under a nitrogen environment, the edetate disodium solution is slowly added dropwise to the acetylcysteine ​​solution, and the mixture is stirred and mixed. The pH value of the solution is adjusted to 7 with hydrochloric acid or sodium hydroxide, and the volume is fixed. The solution is then filtered and packaged using an aluminum membrane with a pore size of 0.22 μm, and sterilized with high-pressure steam at 120° C. for 15 min to obtain the product.

[0068] Comparative Example 3

[0069] An acetylcysteine ​​injection comprises the following components in percentage by weight: 4% acetylcysteine, 4% zinc sulfate, 3% tremella polysaccharide and 0.03% disodium edetate, and the remainder is water.

[0070] The preparation method of the above-mentioned acetylcysteine ​​injection comprises the following steps:

[0071] (1) Add zinc sulfate to oxygen-free water for injection at 45° C. under nitrogen atmosphere, stir until dissolved, then add acetylcysteine ​​thereto, stir until dissolved, and adjust the pH of the solution to 7 with sodium hydroxide solution to prepare an acetylcysteine ​​solution;

[0072] (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution;

[0073] (3) adding Tremella polysaccharide to oxygen-free water for injection under a nitrogen environment, stirring until dissolved, to prepare a Tremella polysaccharide solution;

[0074] (4) Under a nitrogen environment, the edetate disodium solution and the Tremella polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, and the mixture is stirred and mixed. The pH value of the solution is adjusted to 7 with hydrochloric acid or sodium hydroxide, and the volume is constant. The mixture is then filtered and packaged using an aluminum membrane with a pore size of 0.22 μm, and sterilized with high-pressure steam at 120° C. for 15 min to obtain the product.

[0075] Test example

[0076] The high performance liquid chromatography method recorded in the 2020 edition of the Chinese Pharmacopoeia was used to carry out quality and stability testing on different injections. During the stability test, the light treatment conditions were 4500Lx and the high temperature treatment conditions were 60°C.

[0077] Related substances testing:

[0078] Chromatographic column: C18 column;

[0079] Mobile phase: 0.01 mol / L phosphate buffer-methanol (95:5);

[0080] Detection wavelength: 210nm;

[0081] Injection volume: 20 μL;

[0082] Flow rate: 1.5ml / min;

[0083] Column temperature: 20°C;

[0084] Among them, the peak time of cysteine ​​is 5-6 minutes, the peak time of N-N'-diacetylcysteine ​​is 10-11 minutes, and the peak time of NS-diacetylcysteine ​​is 13-15 minutes.

[0085] The acetylcysteine ​​injection prepared in Example 1-4 and Comparative Example 1-3 was subjected to quality inspection, and the specific test results are shown in Table 1-2; after the stability test of the injection in Example 1-4 and Comparative Example 1-3 was completed, the quality inspection was continued, and the specific results are shown in Table 3.

[0086]

[0087]

[0088] Table 1: Stability test results

[0089] It can be seen from the results in Table 1 that after the injections in Examples 1-4 and Comparative Examples 1-3 were treated with light and high temperature, the apparent quality of the injections did not change, the pH value of the injections in Examples 1-4 did not change significantly compared with before treatment, and the pH value of the injections in Comparative Examples 1-3 decreased slightly compared with before treatment.

[0090] Table 2: Quality test results

[0091]

[0092] It can be seen from Table 2 that the acetylcysteine ​​injections configured in Examples 1-4 have a higher content of active ingredients and a lower content of related substances, while the content of active ingredients in Comparative Examples 1-3 decreases and the content of related substances increases. It is speculated that after the preparation method is adjusted, the active ingredients are oxidized and degraded during the configuration or disinfection process, resulting in a decrease in the content of the active ingredients.

[0093] Table 3: Results of injection quality test after illumination

[0094]

[0095] Table 4: Injection quality test results after high temperature

[0096]

[0097]

[0098] It can be seen from the results of Tables 3-4 that after the stability test, the content of the active ingredient in the injection of Examples 1-4 is still high, while the content of the active ingredient in the injection of Comparative Examples 1-3 decreases and the content of other substances increases. It is speculated that after the preparation method is adjusted, the stability of acetylcysteine ​​in the injection is insufficient and it is degraded under high temperature or light.

[0099] In summary, the preparation method in the present application can effectively improve the stability of acetylcysteine ​​injection, reduce the degradation caused during storage, and thus prolong the storage time of the injection.

Claims

1. An acetylcysteine ​​injection, characterized in that: The invention comprises the following components in weight percentage: 1%-4% of acetylcysteine, 2%-8% of a stabilizer and 0.01%-0.05% of an antioxidant, and the rest is water.

2. The acetylcysteine ​​injection according to claim 1, characterized in that The invention comprises the following components in percentage by weight: 3%-4% of acetylcysteine, 5%-8% of a stabilizer, 0.02%-0.03% of an antioxidant, and the rest being water for injection.

3. The acetylcysteine ​​injection according to claim 2, characterized in that: The stabilizer includes zinc sulfate and polyporus polysaccharide.

4. The acetylcysteine ​​injection according to claim 3, characterized in that: The mass proportion of the zinc sulfate is 3%-4%, and the mass proportion of the polyporus polysaccharide is 2%-4%.

5. The acetylcysteine ​​injection according to claim 4, characterized in that: The antioxidant is disodium edetate.

6. The method for preparing acetylcysteine ​​injection according to claim 5, characterized in that: The following steps are involved: (1) Add zinc sulfate and acetylcysteine ​​to oxygen-free water for injection in sequence at 40-50° C. and nitrogen environment, stir until dissolved, and adjust the pH of the solution to 6-8 to prepare an acetylcysteine ​​solution; (2) Adding edetate disodium to oxygen-free water for injection under nitrogen atmosphere and stirring until dissolved to prepare edetate disodium solution; (3) Adding Polyporus polysaccharide to anaerobic water for injection under nitrogen atmosphere and stirring until dissolved to prepare Polyporus polysaccharide solution; (4) Under a nitrogen environment, the edetate disodium solution and the polyporus polysaccharide solution are slowly added dropwise to the acetylcysteine ​​solution in sequence, stirred and mixed, fixed to volume, and then filtered, packaged, and sterilized by high-pressure steam to obtain the product.

7. The method for preparing acetylcysteine ​​injection according to claim 6, characterized in that: In step (1), after the zinc sulfate is dissolved, acetylcysteine ​​is added thereto.

8. The method for preparing acetylcysteine ​​injection according to claim 6, characterized in that: The pore size of the filter device in step (4) is 0.22 microns.

9. The method for preparing acetylcysteine ​​injection according to claim 6, characterized in that: The high-pressure steam sterilization temperature is 113-123℃, and the sterilization time is 10-15min.

Citation Information

Patent Citations

  • Acetylcysteine injection and preparation thereof

    CN101239037A

  • Composition for stabilizing bioactive material

    CN107233320A

  • Stable insulin analogue injection and preparation method thereof

    CN109646396A

  • Preparation method of acetylcysteine injection

    CN114681397A

  • Acetylcysteine injection and preparation method thereof

    CN116350581A